[Treatment of dermatological cases with BB-K8 (author's transl)].
Twenty-seven cases were treated with BB-K8, a new derivative of kanamycin acylated with l-(-)-gamma-amino-alpha-hydroxybutyric acid at the C-1 amino group of the 2-deoxystreptamine moiety. The majority of them were acute primary pyoderma and acute secondary pyoderma. BB-K8 was effective in 23 cases (85.2%) out of 27 cases treated and no side effect was encountered. BB-K8 had antibacterial activity against not only Staphylococcus but also Pseudomonas and Klebsiella. Thus, BB-K8 was considered to be effective in acute pyodermic condition.